UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) : August 10, 2006

Encysive Pharmaceuticals Inc.

(Exact name of registrant as specified in its charter)

Delaware
  (State or other jurisdiction
of incorporation) 0-20117
  (Commission
File Number) 13-3532643
  (IRS Employer
Identification No.)

4848 Loop Central Drive, Suite 700, Houston, Texas 77081

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: 713-796-8822

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On August 10, 2006, Encysive Pharmaceuticals Inc. (the “Company”) announced that it was notified that the European Commission has adopted the decision granting marketing authorization for THELIN^® (sitaxentan sodium) in the European Union.

The Company is awaiting the formal decision letter from the European Commission. Following receipt, which is expected soon, the Company will provide further information.

[SIGNATURE PAGE FOLLOWS]

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ENCYSIVE PHARMACEUTICALS INC. (Registrant)
Date: August 10, 2006	/s/ Paul S. Manierre
	Paul S. Manierre
	Vice President and General Counsel

        .